These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 23311989)
41. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Kim A; Nicolau DP; Kuti JL Mycoses; 2011 Sep; 54(5):e301-12. PubMed ID: 20557463 [TBL] [Abstract][Full Text] [Related]
42. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia. Al-Badriyeh D; Liew D; Stewart K; Kong DC Mycoses; 2012 May; 55(3):244-56. PubMed ID: 21790799 [TBL] [Abstract][Full Text] [Related]
43. Voriconazole versus amphotericin B for invasive aspergillosis. Blot F; Edé C; Nitenberg GM N Engl J Med; 2002 Dec; 347(25):2080-1; author reply 2080-1. PubMed ID: 12490695 [No Abstract] [Full Text] [Related]
44. Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis. Harrington R; Lee E; Yang H; Wei J; Messali A; Azie N; Wu EQ; Spalding J Adv Ther; 2017 Jan; 34(1):207-220. PubMed ID: 27913989 [TBL] [Abstract][Full Text] [Related]
45. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Baddley JW; Andes DR; Marr KA; Kauffman CA; Kontoyiannis DP; Ito JI; Schuster MG; Brizendine KD; Patterson TF; Lyon GM; Boeckh M; Oster RA; Chiller T; Pappas PG Med Mycol; 2013 Feb; 51(2):128-35. PubMed ID: 22680976 [TBL] [Abstract][Full Text] [Related]
46. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system. Michallet M; Gangneux JP; Lafuma A; Herbrecht R; Ribaud P; Caillot D; Dupont B; Moreau P; Berger P; O'Sullivan AK J Med Econ; 2011; 14(1):28-35. PubMed ID: 21175376 [TBL] [Abstract][Full Text] [Related]
47. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662 [TBL] [Abstract][Full Text] [Related]
48. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408 [TBL] [Abstract][Full Text] [Related]
49. [Experience with voriconazole in invasive aspergillosis]. Thiel E; Schwartz S Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137 [TBL] [Abstract][Full Text] [Related]
50. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant. Klein KC; Blackwood RA Pediatrics; 2006 Aug; 118(2):e506-8. PubMed ID: 16816005 [TBL] [Abstract][Full Text] [Related]
51. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016 [TBL] [Abstract][Full Text] [Related]
52. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature. Karthaus M Eur J Med Res; 2011 Apr; 16(4):145-52. PubMed ID: 21486728 [TBL] [Abstract][Full Text] [Related]
53. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Stam WB; Aversa F; Kumar RN; Jansen JP Value Health; 2008; 11(5):830-41. PubMed ID: 18494752 [TBL] [Abstract][Full Text] [Related]
54. Invasive aspergillosis: current and future challenges in diagnosis and therapy. Hope WW; Denning DW Clin Microbiol Infect; 2004 Jan; 10(1):2-4. PubMed ID: 14706080 [TBL] [Abstract][Full Text] [Related]
55. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece. Athanasakis K; Petrakis I; Kyriopoulos J J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409 [TBL] [Abstract][Full Text] [Related]
56. Successful management of invasive aspergillosis with voriconazole and amphoteracin B therapy in a patient with acute mycloid leukemia (AML-M2). Manzoor NF; Azim S; Fadoo Z J Pak Med Assoc; 2010 Nov; 60(11):977-9. PubMed ID: 21375212 [TBL] [Abstract][Full Text] [Related]
58. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. Frankenbusch K; Eifinger F; Kribs A; Rengelshauseu J; Roth B J Perinatol; 2006 Aug; 26(8):511-4. PubMed ID: 16871222 [TBL] [Abstract][Full Text] [Related]
59. Amphotericin B is still the drug of choice for invasive aspergillosis. Agarwal R; Singh N Am J Respir Crit Care Med; 2006 Jul; 174(1):102; author reply 102-3. PubMed ID: 16793999 [No Abstract] [Full Text] [Related]
60. An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis. Chow L; Brown NE; Kunimoto D Clin Infect Dis; 2002 Nov; 35(9):e106-10. PubMed ID: 12384856 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]